Synmosa Biopharma Corporation (TPEX:4114)

Synmosa Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,439	1,186	918.56	1,088	868.17	638.35
Short-Term Investments	60.39	120.31	520	310	115	100
Trading Asset Securities	634.48	575.94	211.45	20.1	5.26	7.01
Cash & Short-Term Investments	3,133	1,882	1,650	1,418	988.43	745.35
Cash Growth	71.86%	14.08%	16.38%	43.43%	32.61%	30.74%
Accounts Receivable	1,242	1,252	1,155	1,125	799.64	702.53
Other Receivables	63.91	57.88	48.43	20.86	10.47	16.31
Receivables	1,306	1,310	1,203	1,146	810.11	718.84
Inventory	1,925	1,787	1,651	1,384	1,214	1,239
Prepaid Expenses	35.3	34.54	28.1	-	51.11	47.23
Other Current Assets	5.15	5.31	7	60.84	35.05	231.46
Total Current Assets	6,405	5,019	4,539	4,008	3,099	2,982
Property, Plant & Equipment	5,592	5,589	5,557	5,638	5,662	5,788
Long-Term Investments	318.86	336.48	222.87	223.01	303.48	271.52
Goodwill	62.29	62.29	62.29	71.08	7.27	13.27
Other Intangible Assets	430.35	449.22	496.56	496.8	494.03	536.69
Long-Term Deferred Tax Assets	370.36	363.27	330.56	331.78	329.28	311.7
Other Long-Term Assets	513.65	484.54	519.9	433.53	421.53	473.71
Total Assets	13,693	12,304	11,729	11,203	10,317	10,377
Accounts Payable	516.42	471.02	427.54	446.16	249.58	184.26
Accrued Expenses	420.63	443.36	381.68	368.47	264.64	260.62
Short-Term Debt	793.9	674.89	661.22	584.08	763.77	630.76
Current Portion of Long-Term Debt	68.76	72.33	289.39	584.42	413.9	256.53
Current Portion of Leases	24.17	22.94	23.3	16.7	6.74	6.83
Current Income Taxes Payable	188.43	142.57	118.29	95.54	53.18	54.61
Current Unearned Revenue	187.36	163.72	172.29	173.43	126.87	129.31
Other Current Liabilities	339.75	83.76	44.71	53.91	10.21	36.74
Total Current Liabilities	2,539	2,075	2,118	2,323	1,889	1,560
Long-Term Debt	1,721	1,729	1,400	2,122	2,272	2,804
Long-Term Leases	47.78	49.86	58.66	48.42	6.76	3.84
Long-Term Unearned Revenue	8.84	5.53	2.35	-	-	-
Long-Term Deferred Tax Liabilities	38.36	37.42	35.45	34.52	34.2	35.11
Other Long-Term Liabilities	1.26	1.26	0.53	12.62	0.89	0.86
Total Liabilities	4,364	3,905	3,628	4,554	4,221	4,423
Common Stock	4,643	4,293	4,014	3,437	3,131	2,808
Additional Paid-In Capital	2,793	2,082	2,195	1,425	1,426	1,403
Retained Earnings	1,028	1,096	1,092	1,005	613.43	713.49
Treasury Stock	-205.68	-205.68	-486.96	-486.96	-402.62	-350.87
Comprehensive Income & Other	-68.7	-55.82	-104.78	-68.18	-63.04	-73.45
Total Common Equity	8,191	7,210	6,710	5,312	4,706	4,500
Minority Interest	1,138	1,189	1,391	1,337	1,390	1,455
Shareholders' Equity	9,329	8,399	8,101	6,649	6,095	5,955
Total Liabilities & Equity	13,693	12,304	11,729	11,203	10,317	10,377
Total Debt	2,656	2,549	2,433	3,355	3,463	3,702
Net Cash (Debt)	477.77	-666.47	-782.59	-1,937	-2,474	-2,956
Net Cash Per Share	1.02	-1.44	-1.75	-4.49	-5.69	-6.96
Filing Date Shares Outstanding	500.7	462.21	462.21	429.15	432.91	436.18
Total Common Shares Outstanding	500.7	462.21	462.21	429.15	432.91	436.18
Working Capital	3,865	2,945	2,421	1,686	1,210	1,423
Book Value Per Share	16.36	15.60	14.52	12.38	10.87	10.32
Tangible Book Value	7,698	6,699	6,151	4,744	4,204	3,950
Tangible Book Value Per Share	15.37	14.49	13.31	11.05	9.71	9.06
Land	3,528	3,528	3,528	3,558	3,558	3,567
Buildings	1,623	1,587	1,567	1,558	1,542	1,561
Machinery	2,077	2,050	1,893	1,790	1,696	1,728
Construction In Progress	83.1	89.55	19.08	9.74	62.51	47.32
Leasehold Improvements	85.44	83.19	80.49	78.96	22.62	19.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.